Deeptech Egypt’s Post

In this blog, Martin Roessner, Corporate Vice President of Biostatistics at Parexel, highlights the need for sensitivity in Alzheimer’s trial design, considering the diminishing ability of patients to communicate as the disease progresses. "Nowhere is the patient-first ethos more critical than in developing treatments for Alzheimer’s disease." Explore the use of genomic and biomarker classification, digital technologies, and alternate trial designs to improve efficacy and reduce patient burden. Read the full article here: https://lnkd.in/eKaM6KxG #Alzheimers #PatientsFirst #ParexelBiotech

In this blog, Martin Roessner, Corporate Vice President of Biostatistics at Parexel, highlights the need for sensitivity in Alzheimer’s trial design, considering the diminishing ability of patients to communicate as the disease progresses. "Nowhere is the patient-first ethos more critical than in developing treatments for Alzheimer’s disease." Explore the use of genomic and biomarker classification, digital technologies, and alternate trial designs to improve efficacy and reduce patient burden. Read the full article here: https://lnkd.in/gKiVHqmR #Alzheimers #PatientsFirst #ParexelBiotech

In this blog, Martin Roessner, Corporate Vice President of Biostatistics at Parexel, highlights the need for sensitivity in Alzheimer’s trial design, considering the diminishing ability of patients to communicate as the disease progresses. "Nowhere is the patient-first ethos more critical than in developing treatments for Alzheimer’s disease." Explore the use of genomic and biomarker classification, digital technologies, and alternate trial designs to improve efficacy and reduce patient burden. Read the full article here: https://lnkd.in/ezVPz_rV #Alzheimers #PatientsFirst #ParexelBiotech

In this blog, Martin Roessner, Corporate Vice President of Biostatistics at Parexel, highlights the need for sensitivity in Alzheimer’s trial design, considering the diminishing ability of patients to communicate as the disease progresses. "Nowhere is the patient-first ethos more critical than in developing treatments for Alzheimer’s disease." Explore the use of genomic and biomarker classification, digital technologies, and alternate trial designs to improve efficacy and reduce patient burden. Read the full article here: https://lnkd.in/exSM3Nxz #Alzheimers #PatientsFirst #ParexelBiotech

🔬 The MMRF CoMMpass Study, a decade-long genomic clinical study of over 1,100 #myeloma patients, is the largest dataset of its kind, driving progress in research and patient care. In 2023, 53 publications or abstracts referenced insights from CoMMpass, offering valuable data to researchers and clinicians worldwide. To learn more about our groundbreaking research and read about our findings from this study, visit: https://ow.ly/x74Q50RvgkB #nationalcancerresearchmonth

Transforming Rare Disease Diagnostics: AP-HM's Automated Exome Analysis Success Story with SeqOne 🧬 APHM (Assistance Publique - Hopitaux de Marseille), a leading French university hospital network, has partnered with SeqOne to fully automate exome sequencing, marking a significant advancement in genetic diagnostics for rare diseases. Key Results: ⚡️ Reduced analysis time per sample 📈 Increased capacity: Now processing 1,500 – 2,000 samples annually 🧠 AI-powered analysis delivering enhanced diagnostic accuracy This collaboration not only transforms patient care but sets a new benchmark for molecular labs. It showcases how cutting-edge technology can revolutionize workflows, making precision medicine more accessible than ever. 👉 Dive into the full case study and explore how automation is reshaping the future of healthcare: https://lnkd.in/eCSsJNst #PrecisionMedicine #RareDiseases #Genomics #HealthcareInnovation #NGS #GeneticDiagnostics #PersonalizedMedicine #DigitalHealth #MedTech

this week was so great - I don't even know where to start ! we are midway through #PRECISIONMEDICINEAWARENESSMONTH #PMAM here is a quick recap of what's happened so far ! 💬 multi stakeholder dialogues and webinars we engaged in powerful conversations with patients and healthcare providers - firstly on the Canadian Biomarker Quality Assurance (CBQA) program webinar, "Precision Oncology Diagnostics - Who Pays?", raising critical questions about reimbursement pathways with Carol C. and @shaqil kassam. Arif Ali Awan spoke to the fundamentals of precision medicine, creating an understanding of how personalized treatments are changing patient outcomes Carol C. gave a clear and impactful explanation of biomarkers and DNA - helping us understand these vital indicators that drive targeted treatment strategies. Alexandra T. Greenhill, MD shared fascinating insights on the role of artificial intelligence in precision medicine, discussing how AI can revolutionize data interpretation, streamline patient care, and enhance decision-making processes. and Ashley Girgis, MHI and Natalie Szudy from The Terry Fox Research Institute's Digital Health and Discovery Platform (DHDP) talked to us about the work they are doing on this exciting made in canada 🇨🇦 initiative that enables secure data sharing and facilitates AI-driven advancements in precision medicine. 🎙️ personal experiences and podcasts this week, i also spoke with Robby Spring Yuan Lew Gordon Levine - absolutely MUST LISTEN ! individuals who have transformed their personal cancer journeys into a mission for systemic change. through their advocacy, they’re challenging barriers, sharing their lived experiences, and driving the push for a more inclusive and accessible cancer care system in canada. their stories have also been highlighted during PMAM ! Catalina Lopez-Correa from Genome Canada also shared her perspective as a genomics leader and someone affected by cancer AND got the data sharing conversation started in a spotlight on the topic ! and of course ! 💻 visit knowyourgenome.co for access to all this and more resources, AND join the conversation with #KNOWVEMBER and #PMAM more to come next week !

Mainz BioMed (@mainzbio), a biotech firm specializing in clinical laboratory tests, is making strides in early disease detection and prevention. According to Bill Caragol, the company's CFO, their genetic and genomic tests can reveal patients' unique genetic profiles, enabling doctors to tailor treatments more effectively and ushering in an era of personalized medicine. Caragol recently shared promising data from recent trials, highlighting the potential of their tests to detect cancer and chronic conditions at an early stage. Early detection is crucial, as it allows patients to receive timely treatment and improve their chances of survival. As diagnostic technology advances, Mainz BioMed aims to save lives and reduce healthcare costs through early disease identification. Their innovative approach could revolutionize how we approach cancer and chronic condition management. #biotechnology #cancerprevention #personalmedicine

Unlocking Precision in Cardiovascular Care with Genobal Cardiovascular diseases often have a genetic component, but identifying the root cause can be challenging with traditional diagnostics. At Genobal, we empower healthcare providers with advanced genetic testing solutions designed to uncover hereditary risk factors for cardiovascular disorders. 🔬 Why Genetic Testing Matters Understanding the genetic basis of conditions like: Familial Hypercholesterolemia Hypertrophic Cardiomyopathy Long QT Syndrome Arrhythmogenic Cardiomyopathy ...enables tailored treatment strategies, early interventions, and better outcomes for patients and their families. 🌟 Our Testing Features: ✅ Comprehensive analysis of cardiovascular-related genes ✅ Accurate results with a quick turnaround ✅ Support for clinical interpretation and genetic counseling 📈 With Genobal, you can provide your patients with precision medicine solutions, ensuring they receive the best care based on their unique genetic makeup. 🩺 Partner with us in advancing cardiovascular health! 👉 Get in touch today to learn more about our services. www.genobal.com +92 330 4592 786 #CardiovascularHealth #Genetics #Genobal #PrecisionMedicine #HealthcareInnovation

as we celebrate #PrecisionMedicineAwarenessMonth, the cancer collaborative (colab) le collaboratoire cancer  is inspired by the work of organizations like CCRAN (Colorectal Cancer Resource & Action Network) in driving transformative advancements in cancer care. Their focus on advanced biomarker testing highlights its pivotal role in improving outcomes and shaping a more efficient healthcare system. In this spirit, they have prepared a wonderful resource for us to share during #PMAM available at knowyourgenome.co KEY HIGHLIGHTS FROM CCRAN's efforts include ✅ Driving Collaboration Through Education CCRAN’s Biomarkers Conference brings together patients, caregivers, clinicians, researchers, and policymakers to discuss the importance of timely testing and its impact on patient outcomes. Planning is underway for the 2025 Biomarkers Conference, continuing this essential dialogue. ✅ Economic and Policy Advocacy In collaboration with the Conference Board of Canada, CCRAN is leading a study to evaluate the cost-benefit of CGP across Canada’s top cancer types. This research will provide evidence to drive policy changes that support equitable access to these groundbreaking technologies. read more at knowyourgenome.co